Cart
sales@molnova.com
p38 MAPK Inhibitor
CAS No. 219138-24-6
p38 MAPK Inhibitor( —— )
Catalog No. M34809 CAS No. 219138-24-6
p38 MAPK inhibitor is a potent inhibitor of p38 MAP kinase (IC50 = 35 nM). It inhibits senescence induced by the oncogene RAS.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 134 | Get Quote |
|
| 5MG | 297 | Get Quote |
|
| 10MG | 464 | Get Quote |
|
| 25MG | 656 | Get Quote |
|
| 50MG | 900 | Get Quote |
|
| 100MG | 1170 | Get Quote |
|
| 200MG | 1593 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product Namep38 MAPK Inhibitor
-
NoteResearch use only, not for human use.
-
Brief Descriptionp38 MAPK inhibitor is a potent inhibitor of p38 MAP kinase (IC50 = 35 nM). It inhibits senescence induced by the oncogene RAS.
-
Descriptionp38 MAPK-IN-4 (compound 6) is a p38 MAPK inhibitor with an 50 of 35 nM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
Recptorp38 MAPK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number219138-24-6
-
Formula Weight365.79
-
Molecular FormulaC20H13ClFN3O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 20 mg/mL (54.68 mM; ultrasonic and adjust pH to 2 with 1M HCl)
-
SMILESO=C1C(=C(NN1C2=CC=C(Cl)C=C2)C=3C=CN=CC3)C4=CC=C(F)C=C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. S E de Laszlo, et al. Pyrroles and other heterocycles as inhibitors of p38 kinase. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2689-94.?
molnova catalog
related products
-
methyl 5-(3,4-dimeth...
methyl 5-(3,4-dimethoxyphenyl)isoxazole-3-carboxylate targets MAPK.
-
Ginkgolide A
Ginkgolide A is a highly active PAF antagonist cage molecule that is isolated from the leaves of the Ginkgo biloba tree. Shows potential in a wide variety of inflammatory and immunological disorders.
-
SKLB-163
SKLB-163 acts by downregulating RhoGDI, activating JNK-1 signaling pathway and caspase-3, and reducing phosphorylated Akt and p44/42 MAPK.
